Menu

Blog

Archive for the ‘biotech/medical’ category: Page 2283

Aug 12, 2018

Revolutionary gene therapy could be a miracle cure for deafness

Posted by in category: biotech/medical

Scientists have developed gene therapy that lets deaf mice hear whispers – and humans could be next.

An extreme form of inherited deafness has been cured in the rodents, which could pave the way for life-changing treatments for humans born with gene defects that affect hearing and balance.

In a groundbreaking experiment, scientists used a laboratory-made virus to deliver corrective DNA into the inner ear.

Continue reading “Revolutionary gene therapy could be a miracle cure for deafness” »

Aug 12, 2018

A Nevada woman died from a bug that resisted 26 antibiotics — here’s why it’s so hard to develop new ones

Posted by in category: biotech/medical

Antibiotic resistance is a growing problem. Here’s why it’s so hard to make new antibiotics to tackle the problem head-on.

Read more

Aug 11, 2018

Scientists hail malaria breakthrough as bed nets prove deadly to mosquitoes

Posted by in categories: biotech/medical, innovation

Clinical malaria cases in Burkina Faso drop by 12% after trial of nets treated with new chemical combination.

Read more

Aug 11, 2018

The future of food: Scientists have found a fast and cheap way to edit your edibles’ DNA

Posted by in categories: biotech/medical, food, genetics

Oil without trans-fat? Wheat without gluten? Gene-editing technology can transform the food we eat. But are consumers on board?

Read more

Aug 11, 2018

Waking Up Podcast #129

Posted by in category: biotech/medical

In this episode of the Waking Up podcast, Sam Harris speaks with Dr. Nina Shapiro about the practice of medicine. They discuss the unique resiliency of children, the importance of second opinions, bad doctors, how medical training has changed in recent years, medical uncertainty, risk perception, vaccine safety, and other topics.

Dr. Nina Shapiro is the award-winning Director of Pediatric Otolaryngology and a Professor of Head and Neck Surgery at UCLA. She is featured in The New York Times, Time, The Wall Street Journal, NPR, and CNN.com among others. She is a regular on CBS’s The Doctors. She is the author of Hype: A Doctor’s Guide to Medical Myths, Exaggerated Claims, and Bad Advice – How to Tell What’s Real and What’s Not.

Read more

Aug 10, 2018

Dr. Aubrey de Grey — Rejuvenation is Finally an Industry

Posted by in categories: biotech/medical, life extension

Dr. Aubrey de Grey gives his keynote speech at the Ending Age-Related Diseases 2018 conference in NYC. This was our first conference and we will be back every year from now on.

To learn more about the event check out the conference page here:
https://www.leafscience.org/ending-age-related-diseases-2018/

Read more

Aug 9, 2018

Glucose and the Gut Microbiome

Posted by in category: biotech/medical

Depleting gut microbiome in mice leads to better insulin sensitivity.


Somewhat serendipitously, Salk Institute researchers discovered that depleting the microbiomes of mice causes the animals to have lower levels of blood glucose as well as improved insulin sensitivity [1].

Abstract

Continue reading “Glucose and the Gut Microbiome” »

Aug 8, 2018

Uncertain human consequences in asteroid risk analysis and the global catastrophe threshold

Posted by in categories: asteroid/comet impacts, biotech/medical, existential risks, policy

By pure coincidence, the article by Seth Baum was published just 5 days after a small asteroid exploded over early warning Tule station in Greenland.


This paper studies the risk of collision between asteroids and Earth. It focuses on uncertainty in the human consequences of asteroid collisions, with emphasis on the possibility of global catastrophe to human civilization. A detailed survey of the asteroid risk literature shows that while human consequences are recognized as a major point of uncertainty, the studies focus mainly on physical and environmental dimensions of the risk. Some potential human consequences are omitted entirely, such as the possibility of asteroid explosions inadvertently causing nuclear war. Other human consequences are modeled with varying degrees of detail. Direct medical effects are relatively well-characterized, while human consequences of global environmental effects are more uncertain. The latter are evaluated mainly in terms of a global catastrophe threshold, but such a threshold is deeply uncertain and may not even exist. To handle threshold uncertainty in asteroid policy, this paper adapts the concept of policy boundaries from literature on anthropogenic global environmental change (i.e., planetary boundaries). The paper proposes policy boundaries of 100 m asteroid diameter for global environmental effects and 1 m for inadvertent nuclear war. Other policy implications include a more aggressive asteroid risk mitigation policy and measures to avoid inadvertent nuclear war. The paper argues that for rare events like large asteroid collisions, the absence of robust data means that a wide range of possible human consequences should be considered. This implies humility for risk analysis and erring on the side of caution in policy.

Read more

Aug 8, 2018

Samumed in $438 Million Deal to Develop Anti-agingTherapies

Posted by in categories: biotech/medical, life extension

Today, we were pleased to hear that Samumed, a San Diego-based biotech company working on regenerative medicine, has just raised $438 million towards developing anti-aging therapies.

SAN DIEGO – August 6, 2018 – Samumed, LLC, announced today that it has closed its A-6 Round of equity issuance with $438 million, bringing its total equity raised to date to more than $650 million. The pre-money valuation for the round was $12 billion.

“We appreciate the strong support from our investors,” said Osman Kibar, Ph.D., Chief Executive Officer of Samumed, “and we are now in a fortunate position to both move our later stage programs to commercialization, as well as expand on our earlier stage science and clinical portfolio.”

Read more

Aug 8, 2018

Ichor Therapeutics Announces The Formation of Grapeseed.bio

Posted by in categories: biotech/medical, life extension

Ichor Therapeutics, a life science company in Lafayette, New York, is one of the big players in the world of rejuvenation biotechnologies. Since its founding in 2013, it has been growing and expanding its portfolio of companies working on therapies against the diseases of aging; on August 1, 2018, Ichor announced the formation of its strategic fund, Grapeseed.bio.

What is Grapeseed.bio

This new fund and accelerator program is meant to provide young life science startups with seed funding up to $100,000, technical training, mentorship, and full access to Ichor’s large research laboratory.

Read more